Evidence map›Paper›PMID 40050920›Full record

ArticleJournal of nanobiotechnology2025

ROS-responsive simvastatin nano-prodrug based on tertiary amine-oxide zwitterionic polymer for atherosclerotic therapy.

Haiqin Yang, Mengcheng Guo, Qingran Guan, Lixue Zhang, Man Liu, Haoyu Li, Guanyu Qiao, Qingbiao Yang, Meili Shen, Yapeng Li

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Haiqin YangKey Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun, Jilin, 130012, China.
Mengcheng GuoKey Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun, Jilin, 130012, China.
Qingran GuanKey Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun, Jilin, 130012, China.
Lixue ZhangKey Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun, Jilin, 130012, China.
Man LiuKey Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun, Jilin, 130012, China.
Haoyu LiDepartment of Spine Surgery, The First Hospital of Jilin University, 1 Xinmin Street, Changchun, Jilin, 130021, China.
Guanyu QiaoDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
Qingbiao YangCollege of Chemistry, Jilin University, Changchun, Jilin, 130021, China.
Meili ShenDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China. shenmeili@jlu.edu.cn.
Yapeng LiKey Laboratory of Special Engineering Plastics Ministry of Education, College of Chemistry, Jilin University, Changchun, Jilin, 130012, China. liyapeng@jlu.edu.cn.

Funding

Jilin University Bethune Medical Department 2023B16 and 2022JBGS04National Natural Science Foundation of China Regional Innovation and Development Joint Fund U24A20477Natural Science Foundation of Jilin Province YDZJ202401490ZYTSScience and Technology Research Project of the Education Department of Jilin Province JJKH20241342KJ"Xinghai Project" of China-Japan Friendship Hospital of Jilin University XHYF202304, XHQMX20232
6 · The paper itself

Abstract

Atherosclerosis (AS) is a major cause of cardiovascular disease and is characterized by high levels of reactive oxygen species (ROS) and lipid deposition. This study utilized ROS-responsive oxalate bonds to conjugate simvastatin (SV) and tertiary amine-oxide zwitterionic polymer (OPDH), resulting in the design of a ROS-responsive simvastatin nano-prodrug (OPDH-SV). In vitro experiments have proved that OPDH-SV has excellent stability and low toxicity, can effectively reduce intracellular ROS and lipid levels, and inhibit foam cells formation. In addition, OPDH-SV is able to achieve cell-to-cell transmission through the cell's "endocytosis-efflux" mechanism and target mitochondria. In vivo experiments further confirmed the long-term circulation, targeted enrichment, and reduction of ROS and lipid levels of OPDH-SV in vivo. In summary, OPDH-SV has good biosafety and excellent in vivo therapeutic effect, and is expected to become a new type of anti-atherosclerotic nano-prodrug.

Indexed as

AtherosclerosisNanoparticlesPolymersProdrugsReactive Oxygen SpeciesSimvastatinAminesAnimalsHumansMaleMiceOxidesRAW 264.7 CellsAminesOxidesPolymersProdrugsReactive Oxygen SpeciesSimvastatinActive transcytosisAtherosclerosisLong-acting circulationNano-ProdrugROS response

Identifiers

PMID40050920
PMCPMC11884140

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.